ArticleVaccine2009
Pleiotropic effects of the lpxM mutation in Yersinia pestis resulting in modification of the biosynthesis of major immunoreactive antigens.
Article in Vaccine, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 24 citations in OpenAlex.
- Structure-guided enzymology of the lipid A acyltransferase LpxM reveals a dual activity mechanism.Proceedings of the National Academy of Sciences of the United States of America · 2016Article
- Protective Immunity Elicited by Oral Immunization of Mice withFrontiers in cellular and infection microbiology · 2016Article
- Plague Vaccine Development: Current Research and Future Trends.Frontiers in immunology · 2016Review
- Immunisation of two rodent species with new live-attenuated mutants ofNPJ vaccines · 2016Article
- Pathogenicity of Yersinia pestis synthesis of 1-dephosphorylated lipid A.Infection and immunity · 2013Article
- Deletion of the Braun lipoprotein-encoding gene and altering the function of lipopolysaccharide attenuate the plague bacterium.Infection and immunity · 2013Article
- Rational considerations about development of live attenuated Yersinia pestis vaccines.Current pharmaceutical biotechnology · 2013Review
- Recognition of lipid A variants by the TLR4-MD-2 receptor complex.Frontiers in cellular and infection microbiology · 2013Review
- Plague vaccines: current developments and future perspectives.Emerging microbes & infections · 2012Review
- Lipopolysaccharide of Yersinia pestis, the Cause of Plague: Structure, Genetics, Biological Properties.Acta naturae · 2012Article
- Article
- Bacteriophage-resistant mutants in Yersinia pestis: identification of phage receptors and attenuation for mice.PloS one · 2011Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
19 authors at 9 institutions in 4 countries.
Funding
Abstract
Deletion mutants in the lpxM gene in two Yersinia pestis strains, the live Russian vaccine strain EV NIIEG and a fully virulent strain, 231, synthesise a less toxic penta-acylated lipopolysaccharide (LPS). Analysis of these mutants revealed they possessed marked reductions in expression and immunoreactivity of numerous major proteins and carbohydrate antigens, including F1, Pla, Ymt, V antigen, LPS, and ECA. Moreover, both mutants demonstrated altered epitope specificities of the antigens as determined in immunodot-ELISAs and immunoblotting analyses using a panel of monoclonal antibodies. The strains also differed in their susceptibility to the diagnostic plague bacteriophage L-413C. These findings indicate that the effects of the lpxM mutation on reduced virulence and enhanced immunity of the Y. pestis EV DeltalpxM is also associated with these pleiotropic changes and not just to changes in the lipid A acylation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.